Day 1: October 23

7:45 a.m. - 5:30 p.m.  Registration

8:00 a.m. - 8:30 a.m.  Day 1 Poster Setup
Travel Awardee Posters will stay up for the entire meeting.

8:30 a.m. - 8:45 a.m.  Opening Remarks
Geraldina Dominguez, Ph.D.
National Cancer Institute, NIH

8:45 a.m. - 9:00 a.m.  Welcome
Robert Yarchoan, M.D.
National Cancer Institute, NIH

9:00 a.m. - 10:30 a.m.  Session 1: HPV and Cervical Cancer
Moderators: Joel Palefsky, M.D.
University of California, San Francisco
Mark H. Einstein, M.D.
Rutgers University

9:00 a.m. - 9:30 a.m.  P1. HPV/Vaccine Trial
Douglas R. Lowy, M.D.
National Cancer Institute, NIH

9:30 a.m. - 10:00 a.m.  P2. Cervical Cancer Control in Africa
Hennie Botha, MBChB, M.Med, FCOG, Ph.D.
Stellenbosch University

10:00 a.m. - 10:30 a.m.  P3. Molecular Carcinogenesis of Cervical Cancer: Beyond HPV
Nicolas Wentzensen, M.D., Ph.D.
National Cancer Institute, NIH

10:30 a.m. - 11:00 a.m.  Break and Poster Viewing

11:00 a.m. - 12 noon  Session 2: Gene Therapy and Stem Cell Transplantation
Moderator: Thomas S. Uldrick, M.D.
National Cancer Institute, NIH

11:00 a.m. - 11:30 a.m.  P4. HIV Gene Therapy
Hans-Peter Kiem, M.D., Ph.D.
Fred Hutchinson Cancer Research Center

11:30 a.m. - 12 noon  P5. Hematopoietic Transplantation for Patients With HIV and Hematologic Malignancies
Richard F. Ambinder, M.D., Ph.D.
Johns Hopkins University School of Medicine

12 noon - 1:00 p.m.  Lunch (on your own or lunch boxes)
Day 1 Poster Viewing (Presenters stand by their posters.)

Session 3: Epstein-Barr Virus and Rhesus Rhadinovirus
Moderators:  Ethel Cesarman, M.D., Ph.D.
Weill Cornell Medical College

Erle S. Robertson, Ph.D.
Perelman School of Medicine, University of Pennsylvania

O1. Development of an EBNA1 Inhibitor for the Treatment of HIV-Associated Epstein-Barr Virus-Driven Malignancies
Troy E. Messick, Ph.D.
The Wistar Institute

O2. Tumor Epstein-Barr Virus Status Is Prognostic in Primary Effusion Lymphoma
Kathryn Lurain, M.D.
National Cancer Institute, NIH

O3. Cell Receptor Activation Triggers Caspase-Mediated Cleavage of PIAS1 to Facilitate Epstein-Barr Virus Lytic Replication
Renfeng Li, Ph.D.
Philips Institute for Oral Health Research

O4. Anti-IL-15-Mediated Depletion of NK Cells in Primary SIV Infection Does Not Alter SIV Replication but Accelerates Rhesus Rhadinovirus Pathogenesis
Afram A. Okoye, Ph.D.
Oregon Health & Science University

Break and Poster Viewing

Session 4: KSHV and Kaposi Sarcoma
Moderators:  Dirk Dittmer, Ph.D.
The University of North Carolina at Chapel Hill

Paul M. Lieberman, Ph.D.
The Wistar Institute

P6. KSHV Targets Nuclear Export of mRNA to Regulate Host Gene Expression
Ting-Ting Wu, Ph.D.
University of California, Los Angeles

O5. Manipulation of the Host Iron Regulon by Kaposi Sarcoma Herpesvirus (KSHV)
Ashlee V. Moses, Ph.D.
Oregon Health & Science University

O6. Modulation of Cholesterol Pathway in KSHV Infection
Anna Serquiña, M.D., Ph.D.
National Cancer Institute, NIH
4:30 p.m. - 4:45 p.m.  
O7. Portable Nucleic Acid Amplification Testing as a Means for Diagnosis of Kaposi Sarcoma in Africa  
Jeffrey N. Martin, M.D., M.P.H.  
University of California, San Francisco

4:45 p.m. - 5:00 p.m.  
O8* Kaposi Sarcoma-Associated Herpesvirus (KSHV) Seroprevalence and Antibody Levels in Relation to Haemoglobin and Malaria Among Individuals From Rural Uganda  
Angela Nalwoga, M.Sc. (Ph.D. candidate)  
MRC/UVRI Uganda Research Unit on AIDS

5:00 p.m. - 5:15 p.m.  
O9. T-cell Receptor Sequencing of Tumor-Infiltrating Lymphocytes in Kaposi Sarcoma Tumors Identifies Candidate Tumor-Reactive T-cell Responses  
Warren Phipps, M.D., M.PH.  
Fred Hutchinson Cancer Research Center

5:15 p.m. - 5:30 p.m.  
O10. Exploring the Function and Mechanism of Pomalidomide-Induced Increases in Immune Surface Markers in Primary Effusion Lymphoma Cells  
David A. Davis, Ph.D.  
National Cancer Institute, NIH

5:30 p.m. - 5:45 p.m.  
O11. AMC-070: Lenalidomide Is Safe and Effective in AIDS-Associated Kaposi Sarcoma  
Dirk Dittmer, Ph.D.  
The University of North Carolina at Chapel Hill

5:45 p.m.  
End of Day 1

08* is a travel awardee.
Day 2: October 24

8:00 a.m. - 8:15 a.m.  Day 2 Poster Setup and Viewing

8:15 a.m. - 8:30 a.m.  Welcome Day 2
Geraldina Dominguez, Ph.D.
National Cancer Institute, NIH

8:30 a.m. - 10:00 a.m.  Session 5: Clinical Research and Trials
Moderators:  Lee Ratner, M.D., Ph.D.
Washington University School of Medicine in St. Louis
Richard F. Little, M.D.
National Cancer Institute, NIH

8:30 a.m. - 9:00 a.m.  P7. Development of HIV-Specific T-Cell Therapy: Lessons From Epstein-Barr Virus
Catherine Bollard, MBChB
Children’s Research Institute

9:00 a.m. - 9:30 a.m.  P8. As-Needed Versus Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild or Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067
Thomas Campbell, M.D., Ph.D.
University of Colorado

9:30 a.m. - 9:45 a.m.  O12. Cisplatin and Radiation Therapy in HIV-Infected Women With Locally Advanced Cervical Cancer in Sub-Saharan Africa (AMC-081)
Mark H. Einstein, M.D., M.S.
Rutgers New Jersey Medical School

9:45 a.m. - 10:00 a.m.  O13. Extracellular Vesicles Derived From HIV-Infected T Cells Promote Progression of Non-AIDS-Defining Cancers
Ge Jin, Ph.D.
Case Western Reserve University

10:00 a.m. - 10:30 a.m.  Break and Poster Viewing

10:30 a.m. - 12 noon  Session 6: Epidemiology and Screening
Moderators:  Gypsyamber D’Souza, Ph.D.
Johns Hopkins Bloomberg School of Public Health
Elizabeth Chiao, M.D., M.P.H.
Baylor College of Medicine

10:30 a.m. - 11:00 a.m.  P9. Projected Cancer Incidence and Burden in HIV-Infected Adults in the United States Through 2030
Meredith S. Shiels, Ph.D.
National Cancer Institute, NIH
O14. Elevated Risk of First and Second Primary Cancers Among People With HIV  
Nancy A. Hessol, M.S.P.H.  
University of California, San Francisco

O15. Lung Cancer Mortality Among People Living With HIV in the United States: Impact of Smoking and Smoking Cessation  
Krishna P. Reddy, M.D.  
Massachusetts General Hospital

O16. Prevention and Early Detection of Cervical Cancer in Africa Through Community-Based Self-Administered Screening and Mobile Treatment Provision  
Miriam Nakalembe, MBChB, Ph.D.  
Infectious Diseases Institute, Makerere University

O17. Persistent Anal HPV16/18 Infections as Predictors of High-Grade Anal Lesions in Older MSM  
Hilary K. Hsu, M.P.H.  
University of California, Los Angeles

Lunch (on your own or lunch boxes)

Day 2 Poster Viewing (Presenters stand by their posters.)

Session 7: Polyomaviruses and Immunotherapy  
Moderators: Thomas G. Gross, M.D., Ph.D.  
National Cancer Institute, NIH  
Corey Casper, M.D., M.P.H.  
Fred Hutchinson Cancer Research Center

P10. BK Polyomavirus, APOBEC3B, and Cancer: Molecular Judo Gone Awry?  
Christopher Buck, Ph.D.  
National Cancer Institute, NIH

P11. PD-L1 Inhibition and the Evolving Management of Merkel Cell Carcinoma  
Isaac F. Brownell, M.D., Ph.D.  
National Cancer Institute, NIH

O18*. A Case Series of Nivolumab in Veterans With HIV Infection and Malignancy  
Elaine Chang, M.D.  
Baylor College of Medicine

O19. AMS095: A Phase I Study of Ipilimumab (Ipi) and Nivolumab (Nivo) in Advanced HIV-Associated Solid Tumors (Preliminary Findings)  
Lakshmi N. Rajdev, M.D.  
Albert Einstein College of Medicine and Montefiore Medical Center

Break and Poster Viewing
4:00 p.m. - 5:25 p.m.  **Session 8: Pathogen Host Interactions**
Moderators:  Jennifer Webster-Cyriaque, Ph.D., D.D.S.  
The University of North Carolina at Chapel Hill

Otoniel Martinez-Maza, Ph.D.  
University of California, Los Angeles

4:00 p.m. - 4:20 p.m.  **P12. Epstein-Barr Virus and Malaria Profiles in African Burkitt Lymphoma: What Can We Learn From Array-Based Studies?**  
Sam Mbulaiteye, M.D.  
National Cancer Institute, NIH

4:20 p.m. - 4:35 p.m.  **O20. A Prospective Study of Serum Microbial Translocation and Inflammation-Associated Biomarkers and Risk of AIDS-Related Non-Hodgkin Lymphoma**  
Marta Epeldegui, Ph.D.  
University of California, Los Angeles

4:35 p.m. - 4:50 p.m.  **O21. Identifying Transcriptional and Prognostic Biomarkers of HIV-Associated Diffuse Large B-cell Lymphoma From Malawi**  
Yuri Fedoriw, M.D.  
The University of North Carolina at Chapel Hill

4:50 p.m. - 5:10 p.m.  **P13. KSHV and Co-infections**  
Denise Whitby, Ph.D.  
Frederick National Laboratory for Cancer Research, NIH

5:10 p.m. - 5:25 p.m.  **O22. Strategies to Improve Kaposi Sarcoma Outcomes in Zimbabwe: A Community-Based Clinical Trial of a Training Intervention for Improved Primary Care of AIDS-KS (SIKO study)**  
Margaret Borok, M.D.  
University of Zimbabwe College of Health Sciences

5:25 p.m. - 5:35 p.m.  **Closing Comments**  
Robert Yarchoan, M.D.  
National Cancer Institute, NIH

5:35 p.m.  **Meeting Adjourned**

019* is a travel awardee.